<DOC>
	<DOC>NCT02096081</DOC>
	<brief_summary>The purpose of this study is to show that two FDA-approved botulinum toxin drugs called Xeomin速 and Botox速 can reduce the severity of vertical lines (wrinkles) that appear between the eyebrows (glabellar frown lines).</brief_summary>
	<brief_title>The Treatment of Glabellar Frown Lines</brief_title>
	<detailed_description>This is a prospective, multicenter, randomized, double-blind, parallel group clinical study to investigate the equivalence of incobotulinumtoxinA (Xeomin速) to onabotulinumtoxinA (Botox速) in the treatment of glabellar frown lines.</detailed_description>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Outpatient females 18 to 50 years of age Moderate to severe glabellar frown lines Glabellar Frown Lines at rest rating 3 on the 4point Facial Wrinkle Scale Previous treatment with botulinum toxin Previous treatment with biodegradable fillers in glabellar area within last 12 months Any severe or uncontrolled systemic disease, malignant tumor, or medical history of HIV infection Known hypersensitivity to incobotulinumtoxinA or onabotulinumtoxinA or to any of their excipients Intake of any of the forbidden concomitant medication or other agents that might interfere with neuromuscular function or might interfere with the action of botulinum toxin type within 14 days prior to injection</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Glabellar Frown Lines</keyword>
	<keyword>Frown Lines</keyword>
	<keyword>Facial Wrinkles</keyword>
</DOC>